Intravesical pembrolizumab (Lipella Pharmaceuticals)

N/A

Report date: 2024/04/28 15:39:46

Base Information

Drug NameIntravesical pembrolizumab (Lipella Pharmaceuticals)
Drug Alias NameLP-50 (Lipella Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLipella Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesLipella Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A